Zusammenfassung
Grundlage der pharmakologischen Wirkung einer psychoaktiven Substanz ist die Substanzkonzentration am Wirkort. Für exogene Substanzen (Xenobiotika) ist diese abhängig von den pharmakokinetischen Eigenschaften der Substanz, also der Freisetzung, der Aufnahme in den Körper, der Verteilung und Verstoffwechslung im menschlichen Körper sowie der Elimination aus dem Körper. Dieses Kapitel stellt die grundlegenden Konzepte und die Prozesse, die die Konzentration am Wirkort psychoaktiver Substanz determinieren, qualitativ und quantitativ dar.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006). Astrocyte-endothelial interactions at the blood–brain barrier. Nature Reviews Neuroscience, 7(1), 41–53.
Al Saabi, A., Allorge, D., Sauvage, F. L., Tournel, G., Gaulier, J. M., Marquet, P., & Picard, N. (2013). Involvement of UDP-glucuronosyltransferases UGT1A9 and UGT2B7 in ethanol glucuronidation, and interactions with common drugs of abuse. Drug Metabolism and Disposition, 41(3), 568–574.
Antia, U., Tingle, M. D., & Russell, B. R. (2009). Metabolic interactions with piperazine-based ‚party pill‘ drugs. Journal of Pharmacy and Pharmacology, 61(7), 877–882.
Atkinson, A. J. (2009). Pharmacokinetics. In S. A. Waldman & A. Terzic (Hrsg.), Pharmacology and therapeutics: Principles to practice (S. 193–202). Philadelphia: Saunders Elsevier.
Atkinson, A. J., Ruo, T. I., & Frederiksen, M. C. (1991). Physiological basis of multicompartmental models of drug distribution. Trends in Pharmacological Sciences, 12(3), 96–101.
Beckett, A. H., & Rowland, M. (1965). Urinary exrection kinetics of methylamphetamine in man. Nature, 206(990), 1260–1261.
Bedada, W., de Andrés, F., Engidawork, E., Pohanka, A., Beck, O., Bertilsson, L., Llerena, A., & Aklillu, E. J. (2015). The Psychostimulant Khat (Catha edulis) inhibits CYP2D6 enzyme activity in humans. Journal of Clinical Psychopharmacology, 35(6), 694–699.
Benet, L. Z., & Hoener, B. A. (2002). Changes in plasma protein binding have little clinical relevance. Clinical Pharmacology and Therapeutics, 71(3), 115–121.
Benowitz, N. L., Porchet, H., Sheiner, L., & Jacob, P. (1988). Nicotine absorption and cardiovascular effects with smokeless tobacco use: Comparison with cigarettes and nicotine gum. Clinical Pharmacology and Therapeutics, 44(1), 23–28.
Buxton, I. L. O., & Benet, L. Z. (2011). Pharmacokinetics: The dynamics of drug absorption, distribution, metabolism, and elimination. In L. Brunton, B. Chabner & B. Knollmann (Hrsg.), Goodman & Gilman’s the pharmacological basis of therapeutics (S. 17–39). New York: McGrawHill.
Chang, Y., Moody, D. E., & McCance-Katz, E. F. (2006). Novel metabolites of buprenorphine detected in human liver microsomes and human urine. Drug Metabolism and Disposition, 34(3), 440–448.
Chimalakonda, K. C., Bratton, S. M., Le, V. H., Yiew, K. H., Dineva, A., Moran, C. L., James, L. P., Moran, J. H., & Radominska-Pandya, A. (2011). Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases. Drug Metabolism and Disposition, 39(10), 1967–1976.
Chimalakonda, K. C., Seely, K. A., Bratton, S. M., Brents, L. K., Moran, C. L., Endres, G. W., James, L. P., Hollenberg, P. F., Prather, P. L., Radominska-Pandya, A., & Moran, J. H. (2012). Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: Identification of novel cannabinoid receptor ligands. Drug Metabolism and Disposition, 40(11), 2174–2184.
Coffman, B. L., King, C. D., Rios, G. R., & Tephly, T. R. (1998). The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metabolism and Disposition, 26(1), 73–77.
Dayer, P., Desmeules, J., Leemann, T., & Striberni, R. (1988). Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). Biochemical and Biophysical Research Communications, 152(1), 411–416.
de Lange, E. C., & Hammarlund-Udenaes, M. (2015). Translational aspects of blood–brain barrier transport and central nervous system effects of drugs: from discovery to patients. Clinical Pharmacology and Therapeutics, 97(4), 380–394.
Engels, F. K., de Jong, F. A., Sparreboom, A., Mathot, R. A., Loos, W. J., Kitzen, J. J., de Bruijn, P., Verwei, J., & Mathijssen, R. H. (2007). Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. The Oncologist, 12(3), 291–300.
Erratico, C., Negreira, N., Norouzizadeh, H., Covaci, A., Neels, H., Maudens, K., & Van Nuijs, A. L. (2015). In vitro and in vivo human metabolism of the synthetic cannabinoid AB-CHMINACA. Drug Testing and Analysis, 7(10), 866–876.
Ewald, A. H., & Maurer, H. H. (2008). 2,5-Dimethoxyamphetamine-derived designer drugs: Studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6. Toxicology Letters, 183(1–3), 52–57.
Feyerabend, C., Ings, R. M., & Russel, M. A. (1985). Nicotine pharmacokinetics and its application to intake from smoking. British Journal of Clinical Pharmacology, 19(2), 239–247.
Fisher, M. B., Paine, M. F., Strelevitz, T. J., & Wrighton, S. A. (2001). The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metabolism Reviews, 33(3–4), 273–297.
Flockhart, D. A. (2007). Drug interactions: Cytochrome P450 drug interaction table. Indiana University School of Medicine. http://medicine.iupui.edu/clinpharm/ddis/clinical-table. Zugegriffen am 01.12.2015.
Foster, D. J., Somogyi, A. A., & Bochner, F. (1999). Methadone N-demethylation in human liver microsomes: Lack of stereoselectivity and involvement of CYP3A4. British Journal of Clinical Pharmacology, 47(4), 403–412.
Gerber, J. G., Rhodes, R. J., & Gal, J. (2004). Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality, 16(1), 36–44.
Gonzalez, F. J., Coughtrie, M., & Tukey, R. H. (2011). Drug metabolism. In L. Brunton, B. Chabner & B. Knollmann (Hrsg.), Goodman & Gilman’s the pharmacological basis of therapeutics (S. 17–39). New York: McGrawHill.
Guitton, J., Buronfosse, T., Désage, M., Lepape, A., Brazier, J. L., & Beaune, P. (1997). Possible involvement of multiple cytochrome P450S in fentanyl and sufentanil metabolism as opposed to alfentanil. Biochemical Pharmacology, 53(11), 1613–1619.
Holland, M. L., Lau, D. T., Allen, J. D., & Arnold, J. C. (2007). The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. British Journal of Pharmacology, 152(5), 815–824.
Holland, M. L., Allen, J. D., & Arnold, J. C. (2008). Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). European Journal of Pharmacology, 591(1–3), 128–131.
Holm, N. B., Nielsen, L. M., & Linnet, K. (2015). CYP3A4 mediates oxidative metabolism of the synthetic cannabinoid AKB-48. The AAPS Journal, 17(5), 1237–1245.
Hutchinson, M. R., Menelaou, A., Foster, D. J., Coller, J. K., & Somogyi, A. A. (2004). CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. British Journal of Clinical Pharmacology, 57(3), 287–297.
Jiang, R., Yamaori, S., Takeda, S., Yamamoto, I., & Watanabe, K. (2011). Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Science, 89(5–6), 165–170.
Jiang, R., Yamaori, S., Okamoto, Y., Yamamoto, I., & Watanabe, K. (2013). Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metabolism and Pharmacokinetics, 28(4), 332–338.
Jushchyshyn, M. I., Kent, U. M., & Hollenberg, P. F. (2003). The mechanism-based inactivation of human cytochrome P450 2B6 by phencyclidine. Drug Metabolism and Disposition, 31(1), 46–52.
Kharasch, E. D., Hoffer, C., Whittington, D., & Sheffels, P. (2004). Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clinical Pharmacology and Therapeutics, 76(3), 250–269.
Laurenzana, E. M., & Owens, S. M. (1997). Metabolism of phencyclidine by human liver microsomes. Drug Metabolism and Disposition, 25(5), 557–563.
Lunell, E., Molander, L., Ekberg, K., & Wahren, J. (2000). Site of nicotine absorption from a vapour inhaler-comparison with cigarette smoking. European Journal of Clinical Pharmacology, 55(10), 737–741.
Martinez, M. N., & Amidon, G. L. (2002). A mechanistic approach to understanding the factors affecting drug absorption: A review of fundamentals. Journal of Clinical Pharmacology, 42(6), 620–643.
Maurer, H. H., Bickeboeller-Friedrich, J., Kraemer, T., & Peters, F. T. (2000). Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs (‚Ecstasy‘). Toxicology Letters, 112(113), 133–142.
Meyer, M. R., Bach, M., Welter, J., Bovens, M., Turcant, A., & Maurer, H. H. (2013). Ketamine-derived designer drug methoxetamine: Metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSn. Analytical and Bioanalytical Chemistry, 405(19), 6307–6321.
Morrissey, K. M., Wen, C. C., Johns, S. J., Zhang, L., Huang, S. M., & Giacomini, K. M. (2012). The UCSF-FDA TransPortal: A public drug transporter database. Clinical Pharmacology and Therapeutics, 92(5), 545–546.
Ndikum-Moffor, F. M., Schoeb, T. R., & Roberts, S. M. (1998). Liver toxicity from norcocaine nitroxide, an N-oxidative metabolite of cocaine. Journal of Pharmacology and Experimental Therapeutics, 284(1), 413–419.
Nebert, D. W., Nelson, D. R., Coon, M. J., Estabrook, R. W., Feyereisen, R., Fujii-Kuriyama, Y., Gonzalez, F. J., Guengerich, F. P., Gunsalus, I. C., & Johnson, E. F. (1991). The P450 superfamily: Update on new sequences, gene mapping, and recommended nomenclature. DNA and Cell Biology, 10, 1–14.
Negreira, N., Erratico, C., Kosjek, T., van Nuijs, A. L., Heath, E., Neels, H., & Covaci, A. (2015). In vitro phase I and phase II metabolism of α-pyrrolidinovalerophenone (α-PVP), methylenedioxypyrovalerone (MDPV) and methedrone by human liver microsomes and human liver cytosol. Analytical and Bioanalytical Chemistry, 407(19), 5803–5816.
Nielsen, L. M., Holm, N. B., Olsen, L., & Linnet, K. (2015). Cytochrome P450-mediated metabolism of the synthetic cannabinoids UR-144 and XLR-11. Drug Testing and Analysis. doi:10.1002/dta.1860.
Nishimura, M., & Naito, S. (2005). Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metabolism and Pharmacokinetics, 20(6), 452–477.
Norberg, A., Jones, A. W., Hahn, R. G., & Gabrielsson, J. L. (2003). Role of variability in explaining ethanol pharmacokinetics: Research and forensic applications. Clinical Pharmacokinetics, 42(1), 1–31.
O'Mathúna, B., Farré, M., Rostami-Hodjegan, A., Yang, J., Cuyàs, E., Torrens, M., Pardo, R., Abanades, S., Maluf, S., Tucker, G. T., & de la Torre, R. (2008). The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. Journal of Clinical Psychopharmacology, 28(5), 523–529.
Paine, M. F., Hart, H. L., Ludington, S. S., Haining, R. L., Rettie, A. E., & Zeldin, D. C. (2006). The human intestinal cytochrome P450 „pie“. Drug Metabolism and Disposition, 34(5), 880–886.
Pedersen, A. J., Reitzel, L. A., Johansen, S. S., & Linnet, K. (2013a). In vitro metabolism studies on mephedrone and analysis of forensic cases. Drug Testing and Analysis, 5(6), 430–438.
Pedersen, A. J., Petersen, T. H., & Linnet, K. (2013b). In vitro metabolism and pharmacokinetic studies on methylone. Drug Metabolism and Disposition, 41(6), 1247–1255.
Pellinen, P., Honkakoski, P., Stenbäck, F., Niemitz, M., Alhava, E., Pelkonen, O., Lang, M. A., & Pasanen, M. (1994). Cocaine N-demethylation and the metabolism-related hepatotoxicity can be prevented by cytochrome P450 3A inhibitors. European Journal of Pharmacology, 270(1), 35–43.
Peters, F. T., Meyer, M. R., Theobald, D. S., & Maurer, H. H. (2007). Identification of cytochrome P450 enzymes involved in the metabolism of the new designer drug 4'-methyl-alpha-pyrrolidinobutyrophenone. Drug Metabolism and Disposition, 36(1), 163–168.
Picard, N., Cresteil, T., Djebli, N., & Marquet, P. (2005). In vitro metabolism study of buprenorphine: Evidence for new metabolic pathways. Drug Metabolism and Disposition, 33(5), 689–695.
Rowland, M., & Towzer, T. N. (2011a). Membranes and distribution. In M. Rowland & T. N. Towzer (Hrsg.), Clinical pharmacokinetics and pharmacodynamics: Concepts and applications (S. 73–110). Baltimore/Philadelphia: Lippincott Williams & Wilkins.
Rowland, M., & Towzer, T. N. (2011b). Elimination. In M. Rowland & T. N. Towzer (Hrsg.), Clinical pharmacokinetics and pharmacodynamics: Concepts and applications (S. 111–157). Baltimore/Philadelphia: Lippincott Williams & Wilkins.
Rowland, M., & Towzer, T. N. (2011c). Multiple dosing regimens. In M. Rowland & T. N. Towzer (Hrsg.), Clinical pharmacokinetics and pharmacodynamics: Concepts and applications (S. 293–329). Baltimore/Philadelphia: Lippincott Williams & Wilkins.
Rowland, M., & Towzer, T. N. (2011d). Absorption. In M. Rowland & T. N. Towzer (Hrsg.), Clinical pharmacokinetics and pharmacodynamics: Concepts and applications (S. 183–215). Baltimore/Philadelphia: Lippincott Williams & Wilkins.
Rowland, M., & Towzer, T. N. (2011e). Nonlinearities. In M. Rowland & T. N. Towzer (Hrsg.), Clinical pharmacokinetics and pharmacodynamics: Concepts and applications (S. 445–482). Baltimore/Philadelphia: Lippincott Williams & Wilkins.
Rowland, M., & Towzer, T. N. (2011f). Drug interactions. In M. Rowland & T. N. Towzer (Hrsg.), Clinical pharmacokinetics and pharmacodynamics: Concepts and applications (S. 483–525). Baltimore/Philadelphia: Lippincott Williams & Wilkins.
Samer, C. F., Daali, Y., Wagner, M., Hopfgartner, G., Eap, C. B., Rebsamen, M. C., Rossier, M. F., Hochstrasser, D., Dayer, P., & Desmeules, J. A. (2010). The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. British Journal of Pharmacology, 160(4), 907–918.
Schneider, N. G., Olmstead, R. E., Franzon, M. A., & Lunell, E. (2001). The nicotine inhaler: Clinical pharmacokinetics and comparison with other nicotine treatments. Clinical Pharmacokinetics, 40(9), 661–684.
Staack, R. F., Theobald, D. S., Paul, L. D., Springer, D., Kraemer, T., & Maurer, H. H. (2004a). Identification of human cytochrome P450 2D6 as major enzyme involved in the O-demethylation of the designer drug p-methoxymethamphetamine. Drug Metabolism and Disposition, 32(4), 379–381.
Staack, R. F., Theobald, D. S., Paul, L. D., Springer, D., Kraemer, T., & Maurer, H. H. (2004b). In vivo metabolism of the new designer drug 1-(4-methoxyphenyl)piperazine (MeOPP) in rat and identification of the human cytochrome P450 enzymes responsible for the major metabolic step. Xenobiotica, 34(2), 179–192.
Stogner, J. M., Eassey, J. M., Baldwin, J. M., & Miller, B. L. (2014). Innovative alcohol use: Assessing the prevalence of alcohol without liquid and other non-oral routes of alcohol administration. Drug and Alcohol Dependence, 142, 74–78.
Subrahmanyam, V., Renwick, A. B., Walters, D. G., Young, P. J., Price, R. J., Tonelli, A. P., & Lake, B. G. (2001). Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metabolism and Disposition, 29(8), 1146–1155.
Thomsen, R., Nielsen, L. M., Holm, N. B., Rasmussen, H. B., Linnet, K., & INDICES Consortium. (2015). Synthetic cannabimimetic agents metabolized by carboxylesterases. Drug Testing and Analysis, 7(7), 565–576.
Wandel, C., Kim, R., Wood, M., & Wood, A. (2002). Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology, 96(4), 913–920.
Wang, J. S., & DeVane, C. L. (2003). Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metabolism and Disposition, 31(6), 742–747.
Watanabe, K., Yamaori, S., Funahashi, T., Kimura, T., & Yamamoto, I. (2007). Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Science, 80(15), 1415–1419.
Weiss, J., Sawa, E., Riedel, K. D., Haefeli, W. E., & Mikus, G. (2008). In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6. Naunyn Schmiedebergs Archives of Pharmacology, 378(3), 275–282.
Welter, J., Kavanagh, P., Meyer, M. R., & Maurer, H. H. (2015a). Benzofuran analogues of amphetamine and methamphetamine: Studies on the metabolism and toxicological analysis of 5-APB and 5-MAPB in urine and plasma using GC-MS and LC-(HR)-MS(n) techniques. Analytical and Bioanalytical Chemistry, 407(5), 1371–1388.
Welter, J., Brandt, S. D., Kavanagh, P., Meyer, M. R., & Maurer, H. H. (2015b). Metabolic fate, mass spectral fragmentation, detectability, and differentiation in urine of the benzofuran designer drugs 6-APB and 6-MAPB in comparison to their 5-isomers using GC-MS and LC-(HR)-MS(n) techniques. Analytical and Bioanalytical Chemistry, 407(12), 3457–3470.
Westmoreland C.L., Hoke J.F., Sebel P.S., Hug C.C., Muir K.T. (1993). Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. Anesthesiology, 79(5), 893–903.
Yamaori, S., Kushihara, M., Yamamoto, I., & Watanabe, K. (2010). Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes. Biochemical Pharmacology, 79(11), 1691–1698.
Yamaori, S., Okamoto, Y., Yamamoto, I., & Watanabe, K. (2011a). Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metabolism and Disposition, 39(11), 2049–2056.
Yamaori, S., Ebisawa, J., Okushima, Y., Yamamoto, I., & Watanabe, K. (2011b). Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: Role of phenolic hydroxyl groups in the resorcinol moiety. Life Science, 88(15–16), 730–736.
Yamaori, S., Koeda, K., Kushihara, M., Hada, Y., Yamamoto, I., & Watanabe, K. (2012). Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity. Drug Metabolism and Pharmacokinetics, 27(3), 294–300.
Yamaori, S., Okushima, Y., Yamamoto, I., & Watanabe, K. (2014). Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chemico-Biological Interactions, 215, 62–68.
Yamaori, S., Kinugasa, Y., Jiang, R., Takeda, S., Yamamoto, I., & Watanabe, K. (2015). Cannabidiol induces expression of human cytochrome P450 1A1 that is possibly mediated through aryl hydrocarbon receptor signaling in HepG2 cells. Life Science, 136, 87–93.
Yanagihara, Y., Kariya, S., Ohtani, M., Uchino, K., Aoyama, T., Yamamura, Y., & Iga, T. (2001). Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes. Drug Metabolism and Disposition, 29(6), 887–890.
Yubero-Lahoz, S., Pardo, R., Farré, M., O’Mahony, B., Torrens, M., Mustata, C., Pérez-Mañá, C., Carbó, M. L., & de la Torre, R. (2011). Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. Clinical Pharmacokinetics, 50(5), 319–329.
Yubero-Lahoz, S., Pardo, R., Farre, M., Mathuna, B. Ó., Torrens, M., Mustata, C., Perez-Mañá, C., Langohr, K., Carbó, M. L., & de la Torre, R. (2012). Changes in CYP1A2 activity in humans after 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) administration using caffeine as a probe drug. Drug Metabolism and Pharmacokinetics, 27(6), 605–613.
Zhu, H. J., Wang, J. S., Markowitz, J. S., Donovan, J. L., Gibson, B. B., Gefroh, H. A., & Devane, C. L. (2006). Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. Journal of Pharmacology and Experimental Therapeutics, 317(2), 850–857.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer-Verlag GmbH Deutschland
About this chapter
Cite this chapter
Hohmann, N. (2018). Pharmakologische Grundlagen: Das Schicksal psychoaktiver Substanzen im menschlichen Körper. In: von Heyden, M., Jungaberle, H., Majić, T. (eds) Handbuch Psychoaktive Substanzen. Springer Reference Psychologie . Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-55125-3_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-55125-3_2
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-55124-6
Online ISBN: 978-3-642-55125-3
eBook Packages: Psychology (German Language)